149 related articles for article (PubMed ID: 36959376)
1. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study.
Hall LA; McKay SC; Halle-Smith J; Soane J; Osei-Bordom DC; Goodburn L; Magill L; Pinkney T; Radhakrishna G; Valle JW; Corrie P; Roberts KJ;
Br J Cancer; 2023 May; 128(10):1922-1932. PubMed ID: 36959376
[TBL] [Abstract][Full Text] [Related]
2. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States.
Paluri R; Laursen A; Gaeta J; Wang S; Surinach A; Cockrum P
Oncologist; 2022 Jun; 27(6):e518-e523. PubMed ID: 35285490
[TBL] [Abstract][Full Text] [Related]
3. Age and prognosis in patients with pancreatic cancer: a population-based study.
van Dongen JC; van der Geest LGM; de Meijer VE; van Santvoort HC; de Vos-Geelen J; Besselink MG; Groot Koerkamp B; Wilmink JW; van Eijck CHJ;
Acta Oncol; 2022 Mar; 61(3):286-293. PubMed ID: 34935577
[TBL] [Abstract][Full Text] [Related]
4. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
6. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
7. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
9. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.
Fornacon-Wood I; Banfill K; Ahmad S; Britten A; Carson C; Dorey N; Hatton M; Hiley C; Thippu Jayaprakash K; Jegannathen A; Kidd AC; Koh P; Panakis N; Peedell C; Peters A; Pope A; Powell C; Stilwell C; Thomas B; Toy E; Wicks K; Wood V; Yahya S; Price G; Faivre-Finn C
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):e593-e600. PubMed ID: 37507280
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract][Full Text] [Related]
11. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
12. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
13. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma.
Anteby R; Blaszkowsky LS; Hong TS; Qadan M
Ann Surg Oncol; 2023 Apr; 30(4):2473-2481. PubMed ID: 36585536
[TBL] [Abstract][Full Text] [Related]
14. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study.
Moffat GT; Coyne Z; Albaba H; Aung KL; Dodd A; Espin-Garcia O; Moura S; Gallinger S; Kim J; Fraser A; Hutchinson S; Moulton CA; Wei A; McGilvray I; Dhani N; Jang R; Elimova E; Moore M; Prince R; Knox J
Curr Oncol; 2024 May; 31(5):2589-2597. PubMed ID: 38785475
[No Abstract] [Full Text] [Related]
15. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases.
Altman AM; White MJ; Marmor S; Shukla D; Chang K; Lou E; LaRocca CJ; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Cancer Control; 2022; 29():10732748221109991. PubMed ID: 35839251
[TBL] [Abstract][Full Text] [Related]
16. Impact of Immunotherapy after Resection of Pancreatic Cancer.
Tran TB; Maker VK; Maker AV
J Am Coll Surg; 2019 Jul; 229(1):19-27.e1. PubMed ID: 30742911
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
[TBL] [Abstract][Full Text] [Related]
18. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience.
McKay SC; Pathak S; Wilkin RJW; Kamarajah SK; Wigmore SJ; Rees J; Dunne DFJ; Garcea G; Ahmad J; de Liguori Carino N; Sultana A; Silva M; Lykoudis P; Nasralla D; Milburn J; Shah N; Kocher HM; Bhogal R; Baron RD; Navarro A; Halle-Smith J; Al-Sarireh B; Sen G; Jamieson NB; Briggs C; Stell D; Aroori S; Bowles M; Kanwar A; Harper S; Menon K; Prachalias A; Srinivasan P; Frampton AE; Jones C; Arshad A; Tait I; Spalding D; Young AL; Durkin D; Ghods-Ghorbani M; Sutcliffe RP; Roberts KJ
HPB (Oxford); 2021 Nov; 23(11):1656-1665. PubMed ID: 34544628
[TBL] [Abstract][Full Text] [Related]
19. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.
Brown ZJ; Labiner HE; Shen C; Ejaz A; Pawlik TM; Cloyd JM
J Surg Oncol; 2022 Feb; 125(2):185-193. PubMed ID: 34599756
[TBL] [Abstract][Full Text] [Related]
20. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
